Drug Database
Back to search

Netherlands· NL-2330fb857648

Rukobia 600 mg tabletten met verlengde afgifte

A fostemsavir product containing fostemsavir tromethamine, registered in Netherlands by ViiV healthcare B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC J05AX29

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRukobia 600 mg tabletten met verlengd…ATCJ05AX29REGISTER NO.NL-2330fb857648PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about fostemsavir tromethamineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Fostemsavir is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AX29 (fostemsavir), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search fostemsavir products by name

Fostemsavir · ATC J05AX29

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
FOSTEMSAVIR TROMETHAMINE
Manufacturer
ViiV healthcare B.V.
Country
Netherlands (NL)
ATC code
J05AX29
ATC class
Fostemsavir
Defined daily dose
1.2 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/20/1518

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

232 interactions on record for fostemsavir.

Graded by severity as the source publishes them — 42 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check fostemsavir against other medicinesHow interaction checks work

Fostemsavir · interactions on record

232 records

  • 42 severe
  • 168 moderate
  • 22 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fostemsavir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fostemsavir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rukobia
  • Liechtenstein · Rukobia
  • Norway · Rukobia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/212b4549-5b69-49a2-b86b-995bae199282
GET /v1/drugs/212b4549-5b69-49a2-b86b-995bae199282?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet met verlengde afgifte",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/rukobia-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Fostemsavir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126217",
  "excipients": [
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE 2208 (Release controlling polymer), K4M (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "FOSTEMSAVIR TROMETHAMINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2021/02/04",
  "procedure_number": "EMEA/H/C/005011",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/20/1518",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about fostemsavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console